Meenakshi Devidas

Sep 11, 2024 | nature.com | Susan R. Rheingold |Deepa Bhojwani |Xinxin Xu |Meenakshi Devidas |Brent L. Wood |Patrick Brown | +5 more

AbstractLimited prognostic factors have been associated with overall survival (OS) post-relapse in childhood Acute Lymphoblastic Leukemia (ALL). Patients enrolled on 12 Children’s Oncology Group frontline ALL trials (1996–2014) were analyzed to assess for additional prognostic factors associated with OS post-relapse. Among 16,115 patients, 2053 (12.7%) relapsed. Relapse rates were similar for B-ALL (12.5%) and T-ALL (11.2%) while higher for infants (34.2%).

Sep 11, 2024 | nature.com | Susan R. Rheingold |Deepa Bhojwani |Xinxin Xu |Meenakshi Devidas |Brent L. Wood |Patrick Brown | +5 more

AbstractLimited prognostic factors have been associated with overall survival (OS) post-relapse in childhood Acute Lymphoblastic Leukemia (ALL). Patients enrolled on 12 Children’s Oncology Group frontline ALL trials (1996–2014) were analyzed to assess for additional prognostic factors associated with OS post-relapse. Among 16,115 patients, 2053 (12.7%) relapsed. Relapse rates were similar for B-ALL (12.5%) and T-ALL (11.2%) while higher for infants (34.2%).

Dec 7, 2023 | nature.com | Meenakshi Devidas |Mignon L. Loh |Naomi J. Winick |Stephen P. Hunger |William Carroll

AbstractOsteonecrosis is a significant toxicity of acute lymphoblastic leukemia (ALL) therapy. In retrospective analyses, superior event-free survival was noted among affected adolescents in an earlier trial. We prospectively assessed osteonecrosis incidence, characteristics, and risk factors in patients 1–30 years with newly diagnosed high-risk B-ALL on COG AALL0232.